Robert John Mentz, MD, FACC
Chief of HF at Duke
Duke University Medical Center, Cardiology Departm

Printed as of 11/22/2026

Disclosures

Personal Commercial (44)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Akros	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
alleviant	Research/Research Grants	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
American Regent	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Amgen	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Amgen Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Bayer Healthcare Pharmaceuticals	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Boston Scientific	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Bristol-Myers Squibb Company	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Cytokinetics	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= $5,000)	
Fast Biomedical	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Gilead Sciences	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Gilead Sciences, Inc.	Other - *Scientific Grant Review Board*	Modest (< $5,000)	*General Cardiology*
GlaxoSmithKline	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
HeartWare	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Janssen	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Luitpold Pharmaceuticals, Inc	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Luitpold Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Medtronic	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Medtronic	Research/Research Grants ‡ *Optivol in LVAD patients*	None ($0)	*Heart Failure and Cardiomyopathies*
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Merck & Co., Inc.	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Novartis Corporation	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Novo Nordisk Inc.	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Otsuka Pharmaceutical Co.	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*
Pharmacosmos	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Pharmacosmos	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
ResMed	Research/Research Grants	None ($0)	*Heart Failure and Cardiomyopathies*

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Respicardia	Research/Research Grants	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Roche	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Rocket	Data Safety Monitoring Board	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Sanofi-Aventis	Research/Research Grants	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Thoratec	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Vifor	Other - *Trial leadership role*	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Vifor	Research/Research Grants	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Windtree	Data Safety Monitoring Board	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
zoll	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 6/12/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 6/12/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 6/12/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 6/12/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.